

# The binding of 1,3-<sup>3</sup>H]-dipropyl-8-cyclopentylxanthine to adenosine A<sub>1</sub> receptors in rat smooth muscle preparations

J.A. Peachey, <sup>1</sup>S.M.O. Hourani & I. Kitchen

Receptors and Cellular Regulation Research Group, School of Biological Sciences, University of Surrey, Guildford, Surrey GU2 5XH

**1** The binding of 1,3-<sup>3</sup>H]-dipropyl-8-cyclopentylxanthine (<sup>3</sup>H]-DPCPX), an antagonist radioligand selective for adenosine A<sub>1</sub> receptors, was studied in rat duodenum, colon muscularis mucosae and longitudinal muscle, urinary bladder and vasa deferentia.

**2** <sup>3</sup>H]-DPCPX bound with high affinity to a single site in all membrane preparations studied with the exception of the rat urinary bladder in which no specific binding was detected. The affinity ( $K_d$ ) of the binding site for <sup>3</sup>H]-DPCPX was similar in all membrane preparations, the colon longitudinal muscle ( $1.18 \pm 0.47$  nM), colon muscularis mucosae ( $0.84 \pm 0.15$  nM), duodenum ( $1.59 \pm 0.18$  nM) and vasa deferentia ( $0.93 \pm 0.17$  nM). The density of <sup>3</sup>H]-DPCPX binding sites was similar in the duodenum ( $38.8 \pm 4$  fmol mg<sup>-1</sup> protein), muscularis mucosae ( $43 \pm 3.5$  fmol mg<sup>-1</sup> protein) and vasa deferentia ( $43.3 \pm 12.2$  fmol mg<sup>-1</sup> protein), but in the longitudinal muscle 6–7 fold more binding sites ( $295 \pm 70$  fmol mg<sup>-1</sup> protein) were identified.

**3** Inhibition studies using DPCPX (0.1–100 nM), N<sup>6</sup>-cyclopentyladenosine (CPA) (0.1–100 nM), 5'-N-ethylcarboxamidoadenosine (NECA) (2 nM–10 μM) and (R)-N<sup>6</sup>-phenylisopropyladenosine (R-PIA) (1 nM–1 μM) to displace the binding of <sup>3</sup>H]-DPCPX at a concentration around the  $K_d$  value (1 nM), demonstrated an order of potency of displacement in all tissues of DPCPX ≥ CPA > R-PIA > NECA. This potency order is characteristic of an A<sub>1</sub> receptor, indicating that <sup>3</sup>H]-DPCPX binds to adenosine A<sub>1</sub> receptors in the rat duodenum, colon and vasa deferentia. Two site analysis revealed that the agonists bind to both a high and low affinity state of the receptor.

**4** The existence of A<sub>1</sub> binding sites in the rat vasa deferentia, colon muscularis mucosae and duodenum, and their absence in the urinary bladder, is consistent with previous functional studies. However, in contrast to the findings of the <sup>3</sup>H]-DPCPX binding assay, no functional response mediated by adenosine A<sub>1</sub> receptors could be detected by measuring contractile or relaxant responses to CPA in the colon longitudinal muscle. The functional significance of the binding sites in this tissue has therefore yet to be determined.

**Keywords:** Rat smooth muscle preparations; <sup>3</sup>H]-DPCPX; radioligand binding; adenosine A<sub>1</sub> receptor; purinoceptors

## Introduction

The P<sub>1</sub>-purinoceptors mediating the action of extracellular adenosine were originally divided into two major subclasses, A<sub>1</sub> and A<sub>2</sub>, on the basis of their differential selectivity for adenosine and adenosine analogues and because of their opposite effects on adenylate cyclase, with A<sub>1</sub> inhibiting and A<sub>2</sub> stimulating enzyme activity (Van Calcar *et al.*, 1979). On A<sub>1</sub> receptors N<sup>6</sup> substituted adenosine analogues such as N<sup>6</sup>-cyclopentyladenosine (CPA) and (R)-N<sup>6</sup>-phenylisopropyladenosine (R-PIA) are more potent than 5' substituted analogues such as 5'-N-ethylcarboxamidoadenosine (NECA), whereas on A<sub>2</sub> receptors the reverse is true. Xanthines such as 8-sulphophenyltheophylline (8-SPT) are antagonists at both A<sub>1</sub> and A<sub>2</sub> receptors, whereas the antagonist 1,3-dipropyl-8-cyclopentylxanthine (DPCPX) has nanomolar affinity at A<sub>1</sub> receptors and micromolar affinity at A<sub>2</sub> receptors and thus effectively discriminates between the two types of receptor. A<sub>2</sub> receptors have been further subdivided into high and low affinity subtypes A<sub>2a</sub> and A<sub>2b</sub> based on their affinity for <sup>3</sup>H]-NECA in radioligand binding studies (Bruns *et al.*, 1986). A<sub>2a</sub> receptors can be distinguished from A<sub>2b</sub> on the basis of the selective activity of some 2-substituted adenosine analogues such as 2-[p-(carboxyethyl)-phenylethylamino]-5'-N-ethylcarboxamidoadenosine (CGS 21680) at A<sub>2a</sub> receptors. More recently, a xanthine-insensitive A<sub>3</sub> receptor has been cloned from rat striatum and has also been shown to be negatively linked to adenylate cyclase (Zhou *et al.*, 1992). For a recent review of adenosine receptor subtypes see Collis & Hourani (1993).

Numerous agonist radioligands are available for A<sub>1</sub> binding studies and binding affinity at A<sub>1</sub> sites has commonly been assessed by use of <sup>3</sup>H]-N<sup>6</sup>-cyclohexyladenosine (CHA) or <sup>3</sup>H]-CPA as the ligand and brain membrane preparations as a source of binding sites (Bruns *et al.*, 1980; Williams *et al.*, 1986). Until recently, the lack of highly selective A<sub>2</sub> agents has generally meant that specific A<sub>2</sub> binding has been determined by the use of a ligand such as <sup>3</sup>H]-NECA, which binds to both A<sub>1</sub> and A<sub>2</sub> receptors, with the binding study carried out in the presence of an A<sub>1</sub> agonist and rat striatum being used as a source of tissue (Bruns *et al.*, 1986; Stone *et al.*, 1988). More recently <sup>3</sup>H]-CGS 21680 has been used to identify A<sub>2a</sub> binding sites in various regions of the brain of both human and rat (Wan *et al.*, 1990), though no agent specific for the low affinity A<sub>2b</sub> site has yet been developed. The affinity of agonist radioligands used in receptor classification, however, may be subject to complications which can be overcome by the use of selective antagonists. Antagonist radioligands bind with high affinity to both agonist defined coupling states of a given receptor and are thus preferable. To this end <sup>3</sup>H]-DPCPX has superseded tritiated A<sub>1</sub> selective agonists, such as <sup>3</sup>H]-CPA, for the study of the binding affinity of A<sub>1</sub> receptors. Indeed, <sup>3</sup>H]-DPCPX has been shown to bind to a single site commensurate with an A<sub>1</sub> receptor, in rat whole brain membranes (Bruns *et al.*, 1987).

Much of the interest in adenosine receptors has focused on its effects in the central nervous system and has involved the use of radioligand binding assays to characterize receptor subtypes. Studies of the peripheral effects of adenosine have

<sup>1</sup> Author for correspondence.

in contrast, used mainly functional studies and very few successful binding studies for adenosine receptors in peripheral tissues have been reported, although binding has been shown to  $A_1$  receptors in the heart (Leid *et al.*, 1988; Martens *et al.*, 1988; Musser *et al.*, 1993), testis (Cushing *et al.*, 1988), uterus (Schiemann *et al.*, 1990; 1991; Smith *et al.*, 1988), human fat cell (Larrouy *et al.*, 1991) and to  $A_2$  receptors in some vascular tissues (Diocee & Souness, 1987; Moritoki *et al.*, 1990).

We have attempted to develop a receptor binding assay in a number of rat peripheral tissues using the antagonist [ $^3$ H]-DPCPX to identify the  $A_1$  adenosine receptor, and to study the distribution of these receptors in various smooth muscle preparations. The rat duodenum, vas deferens and colon muscularis mucosae were chosen as these tissues have previously been shown in functional studies to contain  $A_1$  receptors (Nicholls *et al.*, 1992; Bailey *et al.*, 1992; Hourani *et al.*, 1993). The rat urinary bladder and the longitudinal muscle of the colon were chosen as negative controls as these tissues have been shown in functional studies to contain  $A_{2B}$  receptors (Nicholls *et al.*, 1992; Bailey & Hourani, 1992).

Some of our findings have previously been published in abstract form (Peachey *et al.*, 1994).

## Methods


### Membrane preparation

Adult male Wistar albino rats (200–300g), University of Surrey strain, were killed by cervical dislocation. The duodenum and urinary bladder were dissected out as described in Nicholls *et al.* (1990), the distal colon and the vasa

deferentia were rapidly removed and placed in ice-cold 50 mM Tris HCl buffer (pH 7.4). The longitudinal muscle and the muscularis mucosae of the colon were separated, as described by Bailey & Hourani (1992). Tissues from 25 animals were pooled, all tissues were cleaned and blotted dry to remove any excess buffer, weighed and roughly scissor chopped. Homogenization was performed with a Polytron homogenizer (three 10 s bursts, mid-speed setting), followed by a Potter homogenizer (15 strokes at 1300 r.p.m.). The homogenates were centrifuged for 20 min at 1000g, the pellets discarded and the supernatants recentrifuged at 50,000g for 20 min. The resulting pellets were resuspended in 50 mM Tris HCl buffer and incubated with  $5 \text{ u ml}^{-1}$  adenosine deaminase at room temperature for 30 min before use. Protein estimations were performed according to the method of Lowry *et al.* (1951).

### Binding assays

Saturation experiments were performed in triplicate in polypropylene tubes using a total assay volume of 250  $\mu\text{l}$ . A range of [ $^3$ H]-DPCPX (specific activity  $88.2 \text{ Ci mmol}^{-1}$ ) concentrations (0.05–10 nM) were used and the non-specific binding defined by  $1 \mu\text{M}$  CPA. The reaction was initiated by the addition of homogenate and the mixture incubated for 30 min at temperatures determined to be optimal in pilot studies (duodenum  $0^\circ\text{C}$ , colon muscularis mucosae and longitudinal muscle  $25^\circ\text{C}$  and vas deferens  $35^\circ\text{C}$ ). The reaction was terminated by the addition of ice-cold 50 mM Tris HCl buffer followed by three 2.5 ml washes under vacuum filtration over Whatman GF/B filters using a Brandel Cell Harvester. The filters were removed and placed in scintillation vials, solubilised with 20% Triton in toluene, scintilla-



**Figure 1** Representative time course experiments on (a) colon longitudinal muscle, (b) colon muscularis mucosae, (c) duodenum and (d) vasa deferentia performed at optimal temperatures (colon  $25^\circ\text{C}$ , vasa deferentia  $35^\circ\text{C}$  and duodenum on ice), showing total binding (■) and non-specific binding (●) determined in the presence of  $1 \mu\text{M}$  CPA; reversibility of binding is shown by the addition of  $1 \mu\text{M}$  CPA ( $\downarrow$ ) at 30 min and the subsequent dissociation ( $\blacktriangle$ ) of [ $^3$ H]-DPCPX. For abbreviations in this and subsequent figure legends, see text.

tion fluid (Unisolve E) added and the tubes left overnight to reduce chemiluminescence prior to counting on a Wallac LKB scintillation counter. The results were analysed using LIGAND (Munson & Rodbard, 1980) and the specific binding was subjected to Scatchard transformation for estimation of  $B_{max}$  and  $K_d$ . Inhibition studies were performed with a single concentration (1 nM) of [<sup>3</sup>H]-DPCPX in the presence of increasing concentrations of competing ligands, DPCPX 0.1–100 nM, CPA 0.1–100 nM, R-PIA 1 nM–1 μM and NECA 2 nM–10 μM, and the same procedure was followed as outlined above.


### Functional assays

Adult male Wistar albino rats (200–250 g), University of Surrey strain, were killed by cervical dislocation and the distal colon rapidly excised and placed in Tyrode buffer (ionic composition, mM: Na<sup>+</sup> 149.1, K<sup>+</sup> 2.8, Ca<sup>2+</sup> 1.8, Mg<sup>2+</sup> 2.1, Cl<sup>-</sup> 147.5, H<sub>2</sub>PO<sub>4</sub><sup>-</sup> 0.3, HCO<sub>3</sub><sup>-</sup> 11.9 and glucose 5.6), pregassed with 95% O<sub>2</sub>, 5% CO<sub>2</sub>. The dissection of the longitudinal muscle was carried out as described in Bailey & Hourani (1992). The longitudinal muscle was suspended with the lumen closed, under a resting tension of 1g, in 3.5 ml glass organ bath in gassed Tyrode solution at 32–35°C. Contractions were measured isometrically via an FTO3 force displacement transducer and displayed on a Grass 79D polygraph. The tissues were allowed to equilibrate for 90 min with frequent washing, before the addition of any drugs. Carbachol (CCh) 1 μM was used to contract the tissue and

this response was used as a reference contractile response against which the effects of CPA (1 nM–1 μM) in the absence and presence of DPCPX (1 nM) were assessed. The tissues were dosed non-cumulatively and an interval between doses of 15 min was maintained in all cases. To determine whether CPA had any inhibitory or stimulatory effect on the CCh-induced response, the tissues were treated with CPA either for 1 min prior to the addition of CCh, or when the CCh-induced contraction had achieved a stable plateau. The effects of CPA on field stimulation of the longitudinal muscle by trains of pulses (Grass S48 stimulator, train rate 0.03, duration 10 s, stimulation rate 10 Hz for 1 ms, 70 V) via parallel platinum electrodes (0.3 mm diameter, 0.5 cm apart) were also investigated. In experiments to determine the effects of DPCPX on the CPA-induced response, a control concentration-response curve was carried out, after which the tissues were incubated with 1 nM DPCPX for 30 min and then a second concentration-response curve to CPA was obtained.

### Materials

CPA, R-PIA, NECA and adenosine deaminase (ADA) (Type VI) were obtained from Sigma UK. Ltd, Poole, Dorset; DPCPX from Research Biochemicals, Natick, MA (U.S.A.) and [<sup>3</sup>H]-DPCPX from NEN DuPont UK. Ltd., Stevenage, Hertfordshire. NECA (10 mM) was dissolved in distilled water, CPA (10 mM), DPCPX (10 mM) and R-PIA (10 mM) were dissolved in 20% ethanol and diluted in buffer for use.



**Figure 2** Representative saturation plots performed on (a) colon longitudinal muscle, (b) colon muscularis mucosae, (c) duodenum and (d) vasa deferentia, showing total binding (○), non-specific binding (□) (determined in the presence of 1 μM CPA) and specific binding (●).

All stock solutions were stored frozen at  $-18^{\circ}\text{C}$ . The ADA solution was supplied in 50% glycerol-0.01 M potassium phosphate solution at a concentration of 1000 units in 0.6 ml.

## Results

### Pilot studies

Pilot studies were undertaken to determine the optimal temperature at which to perform the binding assay on each tissue preparation (results not shown). The optimal temperature for binding was  $25^{\circ}\text{C}$  for the colon,  $35^{\circ}\text{C}$  for the vas deferens and on ice ( $0^{\circ}\text{C}$ ) for the duodenum. In the duodenum, at higher temperatures the ligand demonstrated a very rapid binding, followed by an immediate loss of binding. At  $0^{\circ}\text{C}$  the reaction was slower but the binding of the radioligand remained at a steady state. A similar loss of binding was observed in the colon at  $35^{\circ}\text{C}$ , but to a lesser extent, allowing the binding assay to be carried out at  $25^{\circ}\text{C}$ . The reason for the loss of binding at  $35^{\circ}\text{C}$  in these tissues is not known, but could be due to some degradation of the radioligand by the gut tissues, which are known to degrade rapidly other purinoceptor ligands (Bailey & Hourani, 1990;

Hourani *et al.*, 1991). Time course studies showed the binding of  $[^3\text{H}]\text{-DPCPX}$  to be rapid and reach a steady state within 30 min for each tissue preparation; 30 min was therefore used as the incubation time in the rest of the experiments. On addition of unlabelled CPA ( $1\ \mu\text{M}$ ),  $[^3\text{H}]\text{-DPCPX}$  dissociated rapidly from its binding site, with the total amount of  $[^3\text{H}]\text{-DPCPX}$  bound returning to a level equivalent to the non-specific binding after 30 min in each tissue (Figure 1). Reproducible binding was obtained only in fresh tissue preparations, freezing homogenate preparations resulted in a decrease in the density of  $[^3\text{H}]\text{-DPCPX}$  binding sites.

### Saturation experiments

$[^3\text{H}]\text{-DPCPX}$  bound saturably, reversibly and with high affinity to all tissue preparations studied (Figure 2) with the exception of the rat urinary bladder, in which no specific binding of the radioligand was detected (data not shown). Scatchard transformation of specific binding generated monophasic plots (Figure 3) and Hill coefficients were not significantly different from unity, indicating that  $[^3\text{H}]\text{-DPCPX}$  binds to an apparently homogenous population of binding sites. The affinity ( $K_d$ ) of the ligand for each tissue prepara-




Figure 3 Representative Scatchard plots showing the transformation of the data shown in Figure 2 for the specific binding ( $\bullet$ ) of  $[^3\text{H}]\text{-DPCPX}$  in (a) colon longitudinal muscle, (b) colon muscularis mucosae, (c) duodenum and (d) vasa deferentia.

Table 1 Binding affinity ( $K_d$ ) and capacity ( $B_{\text{max}}$ ) for 1,3- $[^3\text{H}]\text{-dipropyl-8-cyclopentylxanthine}$  in various membrane preparations

	Colon LM	Colon MM	Duodenum	Vas deferens
$B_{\text{max}}$ (fmol $\text{mg}^{-1}$ protein)	$295 \pm 70$	$43 \pm 3.5$	$38.8 \pm 4$	$43.3 \pm 12.2$
$K_d$ (nM)	$1.18 \pm 0.47$	$0.84 \pm 0.15$	$1.59 \pm 0.18$	$0.93 \pm 0.17$

Values are the mean  $\pm$  s.e.mean of at least 3 observations. LM, longitudinal muscle; MM, muscularis mucosae.

tion and the density of binding sites ( $B_{max}$ ) were determined from individual Scatchard plots (Scatchard, 1949). The affinity of [<sup>3</sup>H]-DPCPX binding was similar in all membrane preparations with a  $K_d$  of  $\sim 1$  nM (Table 1). The density of binding sites ( $B_{max}$ ) did not differ significantly between the duodenum, vas deferens and colon muscularis mucosae (Table 1). In the longitudinal muscle of the colon however, there were 6–7 fold more binding sites (Table 1).


**Inhibition studies**

Inhibition studies were performed with 1 nM [<sup>3</sup>H]-DPCPX and increasing concentrations of displacing ligands as previously described. Binding was inhibited in a dose-dependent manner by various adenosine receptor ligands, with a rank order of potency of  $DPCPX \geq CPA > R-PIA > NECA$  (Figure 4 and Table 2). This rank order of potency is indicative of binding to an  $A_1$  receptor. Concentration-inhibition curves for unlabelled DPCPX versus [<sup>3</sup>H]-DPCPX were steep with slope factors near unity, whereas the agonists CPA, R-PIA and NECA presented with slope factors ranging from 0.8–0.6, suggesting the presence of more than one binding site. Where a better fit was obtained with a two site

model than with a one site model, the agonist concentration-inhibition curves were fitted to a two site model using LIGAND (Table 3), resulting in  $K_d$  and  $B_{max}$  estimates for both a high and low affinity binding site.

**Functional assays**

Various attempts were made to demonstrate some functional response mediated by  $A_1$  receptors in the longitudinal muscle of the colon (see Figure 5 for representative traces). CPA (1 nM–1  $\mu$ M) added alone had no direct effect on the longitudinal muscle. Preincubating the tissue with CPA (1 nM–1  $\mu$ M) for 1 min before the addition of CCh (1  $\mu$ M) had no effect on the CCh-induced response either in the absence or presence of DPCPX (1 nM). Addition of CPA following contraction of the tissue by CCh was also without effect, except at the higher concentration of CPA (10  $\mu$ M) when a small relaxation was observed. DPCPX (1 nM) did not modify this effect. Field stimulation of the longitudinal muscle by trains of pulses did not induce contractions but after precontracting the tissue with CCh, field stimulation caused relaxations which were neurogenic in origin as they were inhibited by tetrodotoxin (TTX, 1  $\mu$ M). Addition of CPA (1 nM–1  $\mu$ M),



**Figure 4** Inhibition of specific [<sup>3</sup>H]-DPCPX (1nM) binding by (●) DPCPX, (○) CPA, (■) R-PIA or (□) NECA in (a) colon longitudinal muscle, (b) colon muscularis mucosae, (c) duodenum and (d) vasa deferentia. Each point is the mean with s.e.mean of at least 5 observations.

**Table 2**  $K_i$  values (nM) for the inhibition of 1,3-[<sup>3</sup>H]-dipropyl-8-cyclopentylxanthine ([<sup>3</sup>H]-DPCPX) binding by various adenosine receptor ligands

	DPCPX		CPA		R-PIA		NECA	
	$K_i$	Hill slope	$K_i$	Hill slope	$K_i$	Hill slope	$K_i$	Hill slope
Colon LM	2.95 ± 0.26	1.06 ± 0.03	2.96 ± 0.36	0.81 ± 0.08	9.4 ± 1.67	0.72 ± 0.04	50.09 ± 3.48	0.69 ± 0.04
Colon MM	2.8 ± 0.35	0.99 ± 0.03	3.07 ± 0.62	0.82 ± 0.08	12.22 ± 3.34	0.73 ± 0.05	56.37 ± 12.42	0.62 ± 0.04
Duodenum	1.69 ± 0.28	0.97 ± 0.04	4.45 ± 1.02	0.63 ± 0.02	9.19 ± 1.13	0.69 ± 0.02	67.45 ± 8.4	0.59 ± 0.05
Vas deferens	3.58 ± 0.4	1.09 ± 0.05	3.28 ± 0.64	0.74 ± 0.09	13.62 ± 1.98	0.64 ± 0.03	64.48 ± 9.21	0.58 ± 0.06


Values are the mean ± s.e.mean of at least 5 observations, calculated using a one site model. LM, longitudinal, MM, muscularis mucosae.

**Table 3** Two-site analysis of concentration-inhibition curves for agonists in displacing 1,3-[<sup>3</sup>H]-dipropyl-8-cyclopentylxanthine binding:  $K_i$  values (nM) are given for high ( $K_H$ ) and low ( $K_L$ ) affinity sites

	$K_H$	CPA $K_L$	% $K_H$	$K_H$	R-PIA $K_L$	% $K_H$	$K_H$	NECA $K_L$	% $K_H$
Colon LM	0.25	41.99	45.52	2.63 ± 0.75	370 ± 270	62.6 ± 4.9	22.62 ± 3.82	4110 ± 1700	74.7 ± 2.3
Colon MM	0.93 ± 0.56	10.84 ± 1.45	55.2 ± 8.5	1.52 ± 0.04	88.1 ± 45.6	55.7 ± 5.7	10.97 ± 6.18	2190 ± 1560	44 ± 7.5
Duodenum	0.17 ± 0.06	31.58 ± 21.46	36.9 ± 6.6	1.97 ± 0.33	43.9 ± 1.4	50.2 ± 12	11.22 ± 6.32	509.6 ± 205.8	51 ± 10.4
Vas deferens	0.43	9.82	37.7	3.04 ± 0.93	30.25 ± 9.07	58.6 ± 12	18.49 ± 7.8	5350 ± 3500	40.7 ± 5.8

%  $K_H$  shows the percentage of receptors in the high affinity state.

Not all the competition inhibition experiments with CPA were best described by a two site fit, consequently the number of determinations presented for this agonist are reduced compared with Table 2; Colon LM  $n = 1$ , Colon MM  $n = 3$ , duodenum  $n = 4$  and vas deferens  $n = 2$ .



**Figure 5** Representative traces showing the responses of the rat colon longitudinal muscle to CPA ( $\uparrow$ ) (10 nM) in the absence and presence of DPCPX (1 nM) ( $\bullet$ ); (a) the effects of CPA alone; (b) the effect of preincubation with CPA (1 min) followed by contraction induced by CCh (1  $\mu$ M) ( $\blacktriangle$ ); (c) the effect of precontraction with CCh followed by administration of CPA; (d) the effect on nerve stimulation ( $\blacksquare$ ) of CPA added before contraction with CCh (1  $\mu$ M); (e) the effect on nerve stimulation of CPA added after contraction with CCh (1  $\mu$ M).

however, had no effect on the nerve induced response either in the absence or in the presence of DPCPX (1 nM).

## Discussion

Much of the interest in adenosine binding sites has concentrated on the central nervous system, with binding sites commensurate with adenosine  $A_1$  receptors identified in the

brains of a variety of different species including rat, sheep, guinea-pig and cattle (Bruns *et al.*, 1987; Klotz *et al.*, 1991; Leung *et al.*, 1990; Williams & Valentine, 1985). However, limited attention has been paid to adenosine  $A_1$  binding sites in peripheral tissues, although such sites have been identified in myocardial tissue (Leid *et al.*, 1988; Musser *et al.*, 1993), bovine testicular tissue (Cushing *et al.*, 1988), guinea-pig uterus (Schiemann *et al.*, 1990; 1991) and human adipocyte membranes (Larrouy *et al.*, 1991). The limited information regarding adenosine  $A_1$  binding sites in peripheral tissues led us to attempt to develop a radioligand binding assay for  $A_1$  receptors in a variety of rat smooth muscle preparations for which we already had functional data (Bailey *et al.*, 1992; Nicholls *et al.*, 1992; Hourani *et al.*, 1993; Hourani & Jones, 1994). [<sup>3</sup>H]-DPCPX is an antagonist radioligand with 700 fold  $A_1$  over  $A_2$  selectivity (Bruns *et al.*, 1987), and was thus the ligand of choice to characterize the adenosine  $A_1$  binding sites in smooth muscle.

The present study demonstrated [<sup>3</sup>H]-DPCPX binding sites on all membrane preparations studied, with the exception of the rat urinary bladder where no specific [<sup>3</sup>H]-DPCPX binding was detected. However, such a finding was not unexpected as previous functional assays have demonstrated the existence of  $A_2$  receptors only (Nicholls *et al.*, 1992), and furthermore provided a useful method of validation for the assay protocol used. [<sup>3</sup>H]-DPCPX bound with high affinity to the rat duodenum, colon muscularis mucosae and longitudinal muscle and vasa deferentia and in all cases the affinity of the adenosine  $A_1$  binding site for [<sup>3</sup>H]-DPCPX was similar, with  $K_d$  values in the low nM range. This is consistent with previous studies in a number of tissue preparations where the  $K_d$  values have ranged from 0.45 nM for rat brain membranes (Klotz *et al.*, 1990), 1.6 nM for pregnant guinea-pig myometrium (Schiemann *et al.*, 1990) to 3.01 nM for guinea-pig ventricular preparations (Musser *et al.*, 1993). The  $K_d$  values for [<sup>3</sup>H]-DPCPX derived for the duodenum, colon muscularis mucosae and vasa deferentia are also consistent with values previously derived with DPCPX used as an antagonist in functional studies. In these tissues,  $K_B$  values in the region of 1 nM were obtained, although Schild plots were not carried out in the duodenum and vas deferens and the slope of the Schild plot was not unity in the colon muscularis mucosae (Nicholls *et al.*, 1992; Bailey *et al.*, 1992; Hourani *et al.*, 1993). The density of binding sites in these tissues was similar with  $B_{max}$  values ranging from 38–43 fmol  $mg^{-1}$  protein, and this is again consistent with our previous functional studies, where the potency of the  $A_1$  agonist CPA was similar with  $EC_{50}$  values of around 0.1  $\mu$ M for each tissue (Nicholls *et al.*, 1992; Bailey *et al.*, 1992; Hourani *et al.*, 1993). These findings provide evidence that the [<sup>3</sup>H]-DPCPX binding sites do indeed correspond to  $A_1$  receptors.

Further evidence that [<sup>3</sup>H]-DPCPX binds to  $A_1$  receptors was established by inhibition experiments using CPA, DPCPX, NECA and R-PIA. In all tissue preparations studied the order of potency of the competing ligands was DPCPX  $\geq$  CPA  $>$  R-PIA  $>$  NECA, with  $K_i$  values in good agreement with those previously reported (Bruns *et al.*, 1987;

Leid *et al.*, 1988) and this order of potency is characteristic of an A<sub>1</sub> receptor (Collis & Hourani, 1993). Competition for binding of [<sup>3</sup>H]-DPCPX resulted in shallower curves for the agonists than for unlabelled DPCPX suggesting the existence of receptors in both high and low affinity states for the agonists. Indeed when subjected to a two site fit the agonists did display both a high and low affinity binding component of the receptor (Table 3), and such findings are consistent with previous reports demonstrating the existence of multiple affinity binding states for agonists versus [<sup>3</sup>H]-DPCPX binding, in the brain (Bruns *et al.*, 1987; Klotz *et al.*, 1991), adipocyte membranes (Larrouy *et al.*, 1991) and myocardial tissue (Leid *et al.*, 1988).

Species, tissue and ligand differences, in combination with variations in membrane preparations, make it difficult to compare directly the published binding parameters, such as receptor density ( $B_{max}$ ), of radioligands for the adenosine A<sub>1</sub> receptor. Porcine brain has a significantly lower density of A<sub>1</sub> binding sites labelled with [<sup>3</sup>H]-DPCPX than both hamster and sheep brain (Klotz *et al.*, 1991); pregnant guinea-pig myometrium has half the number of A<sub>1</sub> binding sites compared to non-pregnant guinea-pig myometrium (Schiemann *et al.*, 1990; 1991). The density of A<sub>1</sub> binding sites, labelled by [<sup>3</sup>H]-DPCPX, in the rat duodenum, colon muscularis mucosae and vasa deferentia is less than the  $B_{max}$  values reported for brain membranes (0.19–4.09 pmol mg<sup>-1</sup> protein) (Klotz *et al.*, 1991; Oliveira *et al.*, 1991), but is in agreement with the density of A<sub>1</sub> binding sites in myocardial tissue (8.5–75.9 fmol mg<sup>-1</sup> protein) (Musser *et al.*, 1993), thereby suggesting that peripheral tissues have a lower density of A<sub>1</sub> receptors. Further evidence for the diversity in density of A<sub>1</sub> receptors between peripheral and central tissues has been provided by Williams & Valentine (1985), who demonstrated a greater number of high affinity A<sub>1</sub> binding sites labelled with [<sup>3</sup>H]-CHA in the brain membranes than the ileal membranes of guinea-pigs. Surprisingly, we found the highest density of A<sub>1</sub> binding sites in the outer thin walled longitudinal muscle of the rat colon, seven fold higher than the density of binding sites situated on the thick walled inner muscularis mucosae, thereby indicating a heterogeneous density of A<sub>1</sub> binding sites within the structure of the distal colon. Such interstructure variations have been reported elsewhere, as Musser *et al.* (1993) found that in guinea-pig myocardial tissue, the density of A<sub>1</sub> binding sites differed between the atria and ventricles, with the higher density of A<sub>1</sub> binding sites found in the atria.

## References

- BAILEY, S.J., HICKMAN, D. & HOURANI, S.M.O. (1992). Characterisation of the P<sub>1</sub>-purinoceptors mediating contraction of the rat colon muscularis mucosae. *Br. J. Pharmacol.*, **105**, 400–404.
- BAILEY, S.J. & HOURANI, S.M.O. (1990). A study of the purinoceptors mediating contraction in the rat colon. *Br. J. Pharmacol.*, **100**, 753–756.
- BAILEY, S.J. & HOURANI, S.M.O. (1992). Effects of purines on the longitudinal muscle of the rat colon. *Br. J. Pharmacol.*, **105**, 885–892.
- BRUNS, R.F., DALY, J.W. & SNYDER, S.H. (1980). Adenosine receptors in brain membranes: binding of N<sup>6</sup>-cyclohexyl[<sup>3</sup>H]adenosine and 1,3-diethyl-8-[<sup>3</sup>H]phenylxanthine. *Proc. Natl. Acad. Sci. USA*, **77**, 5547–5551.
- BRUNS, R.F., FERGUS, J.H., BADGER, E.W., BRISTOL, J.A., SANTAY, L.A., HARTMAN, J.D., HAYS, S.J. & HUANG, C.L. (1987). Binding of the A<sub>1</sub> selective adenosine antagonist 8-cyclopentyl-1,3-dipropylxanthine to rat brain membranes. *Naunyn-Schmied. Arch. Pharmacol.*, **335**, 59–63.
- BRUNS, R.F., LU, G.H. & PUGSLEY, T.A. (1986). Characterization of the A<sub>2</sub> adenosine receptor labeled by [<sup>3</sup>H]NECA in rat striatal membranes. *Mol. Pharmacol.*, **29**, 331–346.
- COLLIS, M.G. & HOURANI, S.M.O. (1993). Adenosine receptor subtypes. *Trends Pharmacol. Sci.*, **14**, 360–366.
- CUSHING, D.J., MCCONNAUGHEY, M.M. & MUSTAFA, S.J. (1988). Characterization of adenosine binding sites in bovine testicular tissue using 8-cyclopentyl-1,3-[<sup>3</sup>H]dipropylxanthine. *Eur. J. Pharmacol.*, **152**, 353–356.
- DIOCEE, B.K. & SOUNESS, J.E. (1987). Characterization of 5'-N-ethylcarboxamido[<sup>3</sup>H]adenosine binding to pig aorta smooth muscle membranes. *Biochem. Pharmacol.*, **36**, 3621–3627.
- HOURANI, S.M.O., BAILEY, S.J., NICHOLLS, J. & KITCHEN, I. (1991). Direct effects of adenylyl 5'-(β,γ-methylene)diphosphonate, a stable ATP analogue, on relaxant P<sub>1</sub>-purinoceptors in smooth muscle. *Br. J. Pharmacol.*, **104**, 685–690.
- HOURANI, S.M.O., NICHOLLS, J., LEE, S.B.S., HALFHIDE, E.J. & KITCHEN, I. (1993). Characterisation and ontogeny of P<sub>1</sub>-purinoceptors in rat vas deferens. *Br. J. Pharmacol.*, **108**, 754–758.
- HOURANI, S.M.O. & JONES, D.A.D. (1994). Post-junctional excitatory adenosine A<sub>1</sub> receptors in the rat vas deferens. *Gen. Pharmacol.*, **25**, 417–420.
- KLOTZ, K.-N., KEIL, R., ZIMMER, F.J. & SCHWABE, U. (1990). Guanine nucleotide effects on 8-cyclopentyl-1,3-[<sup>3</sup>H]dipropylxanthine binding to membrane bound and solubilized A<sub>1</sub> adenosine receptors of rat brain. *J. Neurochem.*, **54**, 1988–1994.

We would like to thank the Wellcome Trust (Grant ref. 030318/Z/93/Z/1.5) for financial support.

- KLOTZ, K.-N., VOGT, H. & TAWFICK-SCHLIEPER, H. (1991). Comparison of A<sub>1</sub> adenosine receptors in brain from different species by radioligand binding and photoaffinity labelling. *Naunyn Schmied. Arch. Pharmacol.*, **343**, 196–201.
- LARROUY, D., GALITZKY, J. & LAFONTAN, M. (1991). A<sub>1</sub> adenosine receptors in the human fat cell: tissue distribution and regulation of radioligand binding. *Eur. J. Pharmacol.*, **206**, 139–147.
- LEID, M., FRANKLIN, P.H. & MURRAY, T.F. (1988). Labeling of A<sub>1</sub> adenosine receptors in porcine atria with the antagonist radioligand 8-cyclopentyl-1,3-[<sup>3</sup>H]dipropylxanthine. *Eur. J. Pharmacol.*, **147**, 141–144.
- LEUNG, E., JACOBSON, K.A. & GREEN, R.D. (1990). Analysis of agonist-antagonist interactions at A<sub>1</sub> receptors. *Mol. Pharmacol.*, **38**, 72–83.
- LOWRY, O.H., ROSEBROUGH, N.J., FARR, A.L. & RANDALL, R.J. (1951). Protein measurement with the Folin phenol reagent. *J. Biol. Chem.*, **193**, 265–275.
- MARTENS, D., LOHSE, M.J. & SCHWABE, U. (1988). [<sup>3</sup>H]-8-cyclopentyl-1,3-dipropylxanthine binding to A<sub>1</sub> adenosine receptors of intact rat ventricular myocytes. *Circ. Res.*, **63**, 613–620.
- MORITOKI, H., MATSUGI, T., TAKASE, H., UEDA, H. & TANIOKA, A. (1990). Evidence for the involvement of cyclic GMP in adenosine induced, age dependent vasodilatation. *Br. J. Pharmacol.*, **100**, 569–575.
- MUNSON, P.J. & RODBARD, D. (1980). LIGAND: A versatile computerised approach for the characterisation of ligand binding systems. *Anal. Biochem.*, **107**, 220–239.
- MUSSER, B., MORGAN, M.E., LEID, M., MURRAY, T.F., LINDEN, J. & VESTAL, R.E. (1993). Species comparison of adenosine and  $\beta$ -adrenoceptors in mammalian atrial and ventricular myocardium. *Eur. J. Pharmacol.*, **246**, 105–111.
- NICHOLLS, J., HOURANI, S.M.O. & KITCHEN, I. (1990). The ontogeny of purinoceptors in rat urinary bladder and duodenum. *Br. J. Pharmacol.*, **100**, 874–878.
- NICHOLLS, J., HOURANI, S.M.O. & KITCHEN, I. (1992). Characterization of P<sub>1</sub>-purinoceptors on rat duodenum and urinary bladder. *Br. J. Pharmacol.*, **105**, 639–642.
- OLIVEIRA, J.C., SEBASTIAO, A.M. & RIBEIRO, J.A. (1991). Solubilized rat brain adenosine receptors have two high affinity binding sites for 1,3-dipropyl-8-cyclopentylxanthine. *J. Neurochem.*, **57**, 1165–1171.
- PEACHEY, J.A., HOURANI, S.M.O. & KITCHEN, I. (1994). Adenosine A<sub>1</sub> binding sites in rat smooth muscle preparations. *Br. J. Pharmacol.*, **111**, 323P.
- SCATCHARD, G. (1949). The attraction of proteins for small molecules and ions. *Ann. NY. Acad. Sci.*, **51**, 660–672.
- SCHIEMANN, W.P., DOGGWILER, K.O. & BUXTON, I.L.O. (1991). Action of adenosine in estrogen-primed non-pregnant guinea-pig myometrium: characterization of the smooth muscle receptor and coupling to phosphoinositide metabolism. *J. Pharmacol. Exp. Ther.*, **258**, 429–437.
- SCHIEMANN, W.P., WALTHER, J.M. & BUXTON, I.L.O. (1990). On the ability of endogenous adenosine to regulate purine nucleoside receptor binding of antagonists in smooth muscle membranes. *J. Pharmacol. Exp. Ther.*, **265**, 886–892.
- SMITH, M.A., BUXTON, I.L.O. & WESTFALL, D.P. (1988). Pharmacological classification of receptors for adenylyl purines in guinea-pig myometrium. *J. Pharmacol. Exp. Ther.*, **247**, 1059–1063.
- STONE, G.A., JARVIS, M.F., SILLS, M.A., WEEKS, B., SNOWHILL, E.W. & WILLIAMS, M. (1988). Species differences in high affinity adenosine A<sub>2</sub> binding sites in striatal membranes from mammalian brain. *Drug. Dev. Res.*, **15**, 31–46.
- VAN CALKER, D., MÜLLER, M. & HAMPRECHT, B. (1979). Adenosine regulates via two different types of receptor, the accumulation of cyclic AMP in cultured brain cells. *J. Neurochem.*, **33**, 999–1005.
- WAN, W., SUTHERLAND, G.R. & GEIGER, J.D. (1990). Binding of the adenosine A<sub>2</sub> receptor ligand [<sup>3</sup>H]CGS 21680 to human and rat brain: evidence for multiple affinity sites. *J. Neurochem.*, **55**, 1763–1771.
- WILLIAMS, M., BRAUNWALDER, A. & ERICKSON, T.J. (1986). Evaluation of the A<sub>1</sub> selective adenosine radioligand, cyclopentyladenosine (CPA) to rat brain tissue. *Naunyn Schmied. Arch. Pharmacol.*, **332**, 179–183.
- WILLIAMS, M. & VALENTINE, H.L. (1985). Binding of [<sup>3</sup>H]cyclohexyladenosine to adenosine recognition sites in guinea-pig ileal membranes: comparison with binding in brain membranes. *Neurosci. Letts.*, **57**, 79–83.
- ZHOU, Q.-Y., LI, C., OLAH, M.E., JOHNSON, R.A., STILES, G.L. & CIVELLI, O. (1992). Molecular cloning and characterization of an adenosine receptor: the A<sub>3</sub> adenosine receptor. *Proc. Natl. Acad. Sci. USA*, **89**, 7432–7436.

(Received May 25, 1994)

Revised July 21, 1994

Accepted August 15, 1994